Simmons B, et al. - Researchers performed a cohort study comparing consecutive patients with cancer-associated venous thromboembolism (cVTE)(3/1/2013-7/31/2016), enrolled in the Mayo Thrombophilia Clinic Direct Oral Anticoagulants Registry, to contemporary cancer patients receiving enoxaparin. Ninety-eight patients received rivaroxaban and 168 enoxaparin. Gastrointestinal/pancreatic, genitourinary and hematologic cancers were the most common cancers included. This “real-world” experience with cVTE suggested safety and efficacy of rivaroxaban as an alternative to low molecular weight heparin.